AUSTIN, Texas–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the appointments of two pharmaceutical industry veterans to its executive leadership team. Rob Lutz has been appointed Chief Operating Officer, effectively immediately. Scott Wilhoit was appointed Executive Vice President, Global Commercial, effective January 9, 2023, and Dave Lowrance was promoted from Chief Financial Officer to Chief Financial and Administrative Officer, effective December 13, 2022.
“We are pleased that Rob and Scott, two seasoned biotech leaders, have joined the Savara team as we enter a critical phase of development, including completing enrollment of IMPALA-2, delivering top line data by the end of 2Q 2024, and accelerating the development of the global aPAP market,” said Matt Pauls, Chair and CEO, Savara. “Rob is a former investment banker and two-time Chief Business and Financial Officer with nearly two decades of operational leadership experience in the pharmaceutical industry including business development deal execution, capital markets and finance strategy, and commercial analytics in support of rare disease launches. Scott has more than 30 years of commercial experience, much of which has been in the rare disease space, and is an experienced leader who has built strong sales and marketing teams, successfully launched therapeutics for rare diseases, and has expertise in pricing and reimbursement. Our executive leadership team, strengthened by these new appointments, will continue to advance the molgramostim development program and begin planning to support its potential launch.”
About Savara
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).
